Overview
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects
Status:
Completed
Completed
Trial end date:
2010-03-01
2010-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Bristol-Myers Squibb
Criteria
Inclusion Criteria:- Healthy male 18-55
- Women not of child bearing potential, 18-55
Exclusion Criteria:
- History of or current treatment for psychiatric illnesses, substance abuse or
dependence
- History of a clinically significant neurological disorder (e.g., history of stroke,
head trauma, etc.)